We therefore decided to investigate the impact of NAFLD in AD pathogenesis in an AD transgenic mouse model (APP-Tg) and in C57BL/6, wild-type (WT) mice. This evidence concerns the gene APP and metabolic dysfunction-associated steatotic liver disease.